Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25689479 | 0.99 | GBA1 (0.41) | GBA1HPGDRIPK1HCRTR1HCRTR2 | |
| SCHEMBL25689480 | 0.97 | GBA1 (0.39) | GBA1RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24056623 | 0.82 | RIPK1 (0.47) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL25693252 | 0.82 | RIPK1 (0.47) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24056136 | 0.82 | RIPK1 (0.47) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24055485 | 0.81 | RIPK1 (0.46) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24055250 | 0.81 | RIPK1 (0.46) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24055482 | 0.79 | RIPK1 (0.46) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL24055257 | 0.79 | RIPK1 (0.46) | RIPK1HCRTR1HCRTR2 | |
| SCHEMBL25689796 | 0.78 | RIPK1 (0.47) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192662-A1 | Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas | Sironax Ltd. (KY) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192662-A1 | Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas | RIPK1, RIPK3, RIPK4 | GBA1 3834/4885HPGD 2571/4885RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.